Skip to main content
. Author manuscript; available in PMC: 2008 Sep 22.
Published in final edited form as: Cancer Res. 2006 Jan 15;66(2):1181–1190. doi: 10.1158/0008-5472.CAN-04-2962

Table 2.

A. Binding of 48 Clones with Late Stage and Stage ∣ Ovarian Cancer Patient Sera
graphic file with name nihms48954f4.jpg
B. Binding of 17 Clones with Late Stage Ovarian Cancer Patient Sera
graphic file with name nihms48954f5.jpg

NOTE: The binding of a panel of 48 clones with 21 late-stage and 11 stage I ovarian cancer patients was determined. These 48 antigens bound exclusively with serum IgG derived from both late-stage and stage I ovarian cancer patients (including borderline histology) but not with serum IgG from normal controls or patients with benign gynecologic diseases. The gray boxes represent positive binding of phage clones with patient’s sera. TP, total number of patients whose serum IgG bound to each phage clone; Δ, 1:3,000 serum dilution; ▲, 1:30,000 serum dilution; all others were analyzed at a serum dilution of 1:10,000. Histology key: S, serous adenocarcinoma; A, adenocarcinoma not otherwise specified; M, mixed histology; E, endometrioid; B, borderline; C, clear cell. The binding of a panel of 17 clones with 21 late-stage ovarian cancer patients was determined on macroarrays. These 17 antigens bound exclusively with serum IgG derived from late-stage ovarian cancer patients but not with serum IgG from stage I patients, normal controls, or patients with benign gynecologic diseases. The gray boxes represent positive binding of phage clones with patient’s sera. TP, total number of patients whose serum IgG bound to each phage clone; Δ, 1:3,000 serum dilution; all others were analyzed at a serum dilution of 1:10,000.